Skip to Content

NHIA urges commercial payers to cover COVID-19 treatment 

NHIA urges commercial payers to cover COVID-19 treatment 

ALEXANDRIA, Va. – The National Home Infusion Association is urging commercial insurance plans to implement coverage policies for COVID-19 monoclonal antibody therapy used in the home. The association also says CMS’s current administration fee of approximately $310 is insufficient to cover the costs. In a study conducted in February, NHIA determined the cost of providing the therapy is between $584 and $1,746. NHIA encourages payers to work with the home infusion pharmacies in their networks to establish a fair reimbursement rate that considers the value to the plan from preventing hospitalizations and ensures providers can cover their costs. 

Comments

To comment on this post, please log in to your account or set up an account now.